Home » Topics » BioWorld Science, Endocrine/metabolic

BioWorld Science, Endocrine/metabolic
RSS

Gene variants can increase fat, decrease cardiometabolic risk

Feb. 26, 2021

Amicus Therapeutics presents preclinical data for Fabry disease therapeutic AT-GTX-701

Feb. 24, 2021

The Titan Leading Med Tech discovers new GLP-1 receptor agonists

Feb. 24, 2021

Topline data from phase III BRIGHT study of pegunigalsidase alfa for Fabry Disease

Feb. 24, 2021

Positive topline data from pivotal phase III SKYLIGHT 1 and SKYLIGHT 2 studies of fezolinetant

Feb. 22, 2021

Rocket begins phase I study of RP-L401 in infantile malignant osteopetrosis

Feb. 19, 2021

AAV-mediated gene therapy FLT-201 shows robust potency for treating Gaucher disease

Feb. 19, 2021

Immunotherapy targeting AT1R ameliorates experimental insulin resistance

Feb. 19, 2021

ABO-102 demonstrates evidence of clinical benefit in patients with MPS IIIA

Feb. 18, 2021

Highly phosphorylated GCase M-011 exhibits improved potential in Gaucher disease

Feb. 18, 2021

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for May 7, 2026.
News in brief
BioWorld Asia
BioWorld Asia briefs for May 5, 2026
First measles treatment advances as vaccination rates drop
BioWorld
Scientists at the La Jolla Institute for Immunology have identified and characterized human antibodies that neutralize the measles virus by blocking its entry...
Cytospire raises £61M series A to target EGFR in solid tumors
BioWorld
Next-generation T-cell engager (TCE) specialist Cytospire Therapeutics Ltd. has raised £61 million (US$82.7 million) in a series A round, equipping it to advance...
Hantavirus is ‘sentinel’ more than acute pandemic threat
BioWorld
News of eight infections and three deaths so far due to an emerging zoonotic virus has brought back unhappy memories of the early days of SARS-CoV-2. At a press...